ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Generic Drugs Forum 2022 – Day 1, Session 1

Автор: U.S. Food and Drug Administration

Загружено: 2022-05-09

Просмотров: 4599

Описание: FDA presents on the Current State of Generic Drugs and offers practical advice, presenting case studies, and taking a deep dive into the abbreviated new drug application assessment program. Presentations focus on topics such as the pre-ANDA program, generic drug metrics, post-market safety, pre-approval inspections, and global generic drug affairs. Includes Q&A session and a moderated panel discussion.

0.01 – Keynote
12.01 – Office of Generic Drugs Keynote
18:45 – Office of Pharmaceutical Quality Keynote
41:17 – Use of Knowledge-Aided Assessment and Structured Application (KASA) in Drug Product Assessment
1:03:16 - Use of Knowledge-Aided Assessment and Structured Application (KASA) in Drug Product Manufacturing Assessment
1:21:07 - Use of Knowledge-Aided Assessment and Structured Application (KASA) in Biopharmaceutics Assessment
1:40:57 – Integrated Drug Product Assessment: Expectations
2:01:32 – Questions & Panel Discussion


Presenters and Panel:

Janet Woodcock
Principal Deputy Commissioner, Office of the Commissioner, FDA

Sally Choe
Director, Office of Generic Drugs (OGD) | CDER

Michael Kopcha
Director, Office of Pharmaceutical Quality (OPQ) | CDER

Peter Capella
Director, Division of Immediate and Modified Release Products II (DIMRPII), Office of Life Cycle Products (OLDP) |OPQ | CDER

Rakhi Shah
Associate Director, Office of Pharmaceutical Manufacturing Assessment (OPMA) | OPQ | CDER

Kimberly Raines
Branch Chief, Division of Biopharmaceutics, Office of New Drug Products (ONDP) | OPQ | CDER

Mayra Pineiro Sanchez
Senior Pharmaceutical Quality Assessor, Division of Immediate and Modified Release Products II, OLDP | OPQ | CDER

For slides and additional information: https://www.fda.gov/drugs/news-events...

-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.   

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2022 Playlist -    • 2022 CDER Small Business and Industry Assi...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]
Phone - (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Generic Drugs Forum 2022 – Day 1, Session 1

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

Generic Drugs Forum 2022 – Day 1, Session 2

Generic Drugs Forum 2022 – Day 1, Session 2

Roundtable on PMTA Submissions for ENDS Products

Roundtable on PMTA Submissions for ENDS Products

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Generic Drugs Forum 2022 – Day 1, Session 4

Generic Drugs Forum 2022 – Day 1, Session 4

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

Product Specific Guidances (PSGs) (3of16) Generic Drugs Forum 2020

Product Specific Guidances (PSGs) (3of16) Generic Drugs Forum 2020

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Celebrates 120 Years

FDA Celebrates 120 Years

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]